PubMed
Growth hormone-releasing peptide-6 stimulates GH, ACTH, and cortisol release
Arvat et al., 1998
Growth Hormone Releasing Peptide-6
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue that strongly stimulates GH release through ghrelin receptor activation. It is particularly notable for significantly increasing appetite via ghrelin pathway activation — useful in research contexts for body composition changes, catabolic state reversal, and GH deficiency studies. Research use only; not FDA-approved for therapeutic use.
Trend index
Overview
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue that strongly stimulates GH release through ghrelin receptor activation. It is particularly notable for significantly increasing appetite via ghrelin pathway activation — useful in research contexts for body composition changes, catabolic state reversal, and GH deficiency studies. Research use only; not FDA-approved for therapeutic use.
Community
Positive 83% · Neutral 17% · Negative 0%
Median: 200–400 mcg · Most common: 200–400 mcg
Research
PubMed
Arvat et al., 1998
PubMed
Ghigo et al., 2008
Help
This page summarizes 6 anonymized self-reports from PeptIQ users who track GHRP-6, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. GHRP-6 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
Research, primarily in animal models, suggests GHRP-6 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceGHRP-6 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified GHRP-6 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceThe safety and effectiveness of GHRP-6 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhile there are over 200 published studies on GHRP-6, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source